Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.5K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

1.9K
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The immunobiology of cobalt: demonstration of a potential aetiology for inflammatory pseudotumours after metal-on-metal replacement of the hip.

The bone & joint journal·2014
Same author

Breast cancer, side population cells and ABCG2 expression.

Cancer letters·2012
Same author

Differential effects of selenium and knock-down of glutathione peroxidases on TNFα and flagellin inflammatory responses in gut epithelial cells.

Genes & nutrition·2011
Same author

Effects of hay intake and feeding sequence on variables in faeces and faecal water (dry matter, pH value, organic acids, ammonia, buffering capacity) of horses.

Journal of animal physiology and animal nutrition·2009
Same author

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

Oncogene·2009
Same author

ARMS allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast.

Clinical chemistry·2001

Related Experiment Video

Updated: Apr 19, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K

The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.

A Dittrich1, H Gautrey, D Browell

  • 1Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.

Journal of Mammary Gland Biology and Neoplasia
|December 30, 2014
PubMed
Summary

The human epidermal growth factor receptor 2 (HER2) drives tumor growth and resistance in breast cancer. Understanding its complex signaling network is key to developing new therapies.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

888
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Experiment Videos

Last Updated: Apr 19, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

888
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Human epidermal growth factor receptor 2 (HER2) overexpression drives tumor cell survival and proliferation in up to 30% of breast cancer cases.
  • Targeted therapies have been developed to impede HER2 action, focusing on pathways like phosphoinositide-3-kinase (PI3K)/AKT and rat sarcoma/mitogen-activated protein kinase (RAS/MAPK).
  • Drug resistance and disease recurrence remain significant challenges in HER2-positive breast cancer treatment.

Purpose of the Study:

  • To review the intricate signaling network of HER2, encompassing its interactions from transcription to downstream targets.
  • To elucidate the complexity of HER2 signaling, including crosstalk with hormone receptors and feedback loops, contributing to treatment resistance.
  • To explore novel avenues within HER2 signaling for improved understanding and development of more effective breast cancer therapies.

Main Methods:

  • Literature review of current knowledge on HER2 signaling pathways and interactions.
  • Analysis of HER2's role in tumor cell survival, proliferation, and therapeutic resistance.
  • Synthesis of information on HER2's transcriptional regulation, feedback loops, and crosstalk with other signaling molecules.

Main Results:

  • HER2 signaling is characterized by a complex network, including crosstalk with hormone receptors, transcriptional factor functions, and regulation by protein-tyrosine phosphatases.
  • Positive and negative feedback loops significantly contribute to the complexity of the HER2 signaling network.
  • Understanding these intricate interactions is crucial for addressing drug resistance and disease recurrence.

Conclusions:

  • The complexity of the HER2 signaling network presents a major hurdle in overcoming drug resistance and disease recurrence in HER2-positive breast cancers.
  • Further exploration of novel HER2 signaling pathways is essential for developing more effective therapeutic strategies.
  • A comprehensive understanding of HER2 interactions can lead to breakthroughs in treating resistant and recurrent breast cancer.